Cancer research
Mayo Clinic is leading an interventional clinical trial, Phase 2, to investigate the potential benefits of combining therapeutic plasma exchange (TPE) with existing treatments for bladder cancer. The trial aims to recruit 50 participants from the USA and is designed to compare the effectiveness of TPE, followed by enfortumab vedotin
Cancer research
Jiangsu Cancer Hospital has initiated a clinical trial to study the efficacy and safety of Apatolimab Tovolimab combined with regorafenib and paclitaxel as a second-line treatment for patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who have failed immunotherapy combined with chemotherapy. The open-label, multicenter phase II clinical
Cancer research
Researchers at a leading institution are conducting a Phase 2 clinical trial to investigate metabolic glycolytic biomarkers predictive of response to neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC). The trial, led by Saulo B. Silva, Associate Professor, MD, PhD, aims to develop a practical diagnostic approach to improve patient
Cancer research
The Roswell Park Cancer Institute has announced the launch of an interventional clinical trial to study the effectiveness of GB1211 (selvigaltin), an oral galectin-3 inhibitor, in combination with standard of care treatment in patients with relapsed or refractory multiple myeloma. The trial, which has an enrollment of 21 participants from
Cancer research
Hunan Cancer Hospital has launched a Phase 2 clinical trial to evaluate the efficacy and safety of lorlatinib in treating advanced ROS1-positive non-small cell lung cancer (NSCLC) patients with brain metastases. The trial aims to enroll 21 participants from the USA and will assess the intracranial efficacy and safety of
Cancer research
A new study has highlighted a significant issue in pediatric oncology research worldwide. Investigators from Universidad de Manizales in Colombia have found that the global distribution of chimeric antigen receptor (CAR) T-cell therapy for childhood cancer is unequal, with limited access in regions bearing a high burden of disease. The
Cancer research
Researchers from the Chinese Academy of Medical Sciences have conducted a phase I trial investigating the efficacy of autologous CD7 CAR-T cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL). The study, which enrolled 30 patients, demonstrated promising results, with 96% of patients responding to the
Cancer research
Essen Biotech has recently listed a Phase 1/2 clinical trial on ClinicalTrials.gov, aimed at evaluating the safety and efficacy of sequentially administered CD146-targeted and GPC3-targeted CAR-T cell therapy in patients with advanced relapsed or refractory ovarian cancer. The trial, which is currently recruiting 80 participants from the USA,
Cancer research
Mansoura University has initiated an interventional clinical trial to evaluate the efficacy of melatonin concomitant use with neoadjuvant chemotherapy protocols in breast cancer patients. The study aims to investigate the potential anticancer properties of melatonin, which has been reported to exhibit antioxidant, immunomodulating, oncostatic, antiproliferative, and estrogen-modulating properties. The trial
Cancer research
New research from YuceBio Technology Co. Ltd. has shown promising results for the use of neoadjuvant immunochemotherapy in treating cervical cancer. The study, which was published in the journal Signal Transduction and Targeted Therapy, aimed to evaluate the efficacy and safety of combining the anti-programmed cell death protein 1 (PD-1)
Cancer research
BriaCell Therapeutics Corp., a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has announced the addition of Mayo Clinic to its ongoing pivotal Phase 3 clinical study in metastatic breast cancer. The study, which is evaluating BriaCell's lead clinical candidate, Bria-IMT(TM), plus immune checkpoint inhibitor
Cancer research
National Cancer Institute (NCI) has announced an interventional clinical trial to investigate the effectiveness of adding induction chemotherapy to the standard treatment of chemotherapy and radiation for high-risk locally advanced cervical cancer. The Phase 3 trial, led by principal investigator Jyoti S Mayadev, aims to enroll 336 participants from the
